Redwire to Develop Space-Based Drug Development and Manufacturing Platform
28 7월 2022 - 8:00PM
Business Wire
Eli Lilly and Company is first investigator using new
platform
Redwire Corporation (NYSE:RDW), a leader in space infrastructure
for the next generation space economy, announced that it will be
developing new in-space manufacturing technology to provide novel
and flexible services to grow small-batch crystals of protein-based
pharmaceuticals and other key pharmaceutically relevant molecules
for research and production. The Pharmaceutical In-space Laboratory
– Bio-crystal Optimization Xperiment (PIL-BOX) will provide
commercial customers and researchers an innovative platform in
microgravity that could improve the development of pharmaceuticals
and other products. Eli Lilly and Company will be partnering with
Redwire to conduct critical testing during the initial flight
missions for PIL-BOX. Lilly’s investigations will focus on the
development of treatments for diabetes and cardiovascular disease.
Leveraging optimized, space-grown crystals, like those developed
through the PIL-BOX platform, could enable pharmaceutical companies
and researchers to develop new therapies to improve human health
and quality of life on Earth.
"This is an exciting new capability that could unlock new drug
development processes in space that could translate to improved
pharmaceuticals and make a positive impact on human health," said
John Vellinger, Redwire’s Executive Vice President of In-Space
Manufacturing and Operations. "We are harnessing decades worth of
in-space manufacturing expertise to develop new space technologies
that can intersect with the needs of terrestrial markets, like the
pharmaceutical industry, to improve products and ultimately improve
life on Earth."
Understanding crystal growth and design can inform the entire
drug development and design process as pharmaceutical companies
look to deliver new, optimized treatments to help patients on
Earth. Previous spaceflight investigations indicate that growing
crystals in space could yield a more uniform product with fewer
imperfections, which can improve the drug discovery and development
process.
The PIL-BOX platform has exciting implications for advancing
pharmaceutical research and development in space. The technology
builds on Redwire’s extensive space crystallization flight
heritage, which dates back to the space shuttle era through its
Advanced Space Experiment Processor. Recently, Redwire sold its
first space-optimized product—a space-grown optical
crystal—manufactured in its Industrial Crystallization Facility,
which launched to the International Space Station in 2021.
PIL-BOX is being developed in partnership with NASA through its
In Space Production Applications (InSPA) flight demonstrations
program, which is focused on stimulating demand in low-Earth
orbit.
About Redwire
Redwire Corporation (NYSE: RDW) is a leader in space
infrastructure for the next generation space economy, with valuable
IP for solar power generation and in-space 3D printing and
manufacturing. With decades of flight heritage combined with the
agile and innovative culture of a commercial space platform,
Redwire is uniquely positioned to assist its customers in solving
the complex challenges of future space missions. For more
information, please visit www.redwirespace.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220728005336/en/
Media Contact: Tere Riley Tere.Riley@redwirespace.com
321-831-0134
OR
Investors: investorrelations@redwirespace.com
904-425-1431
Redwire (NYSE:RDW)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Redwire (NYSE:RDW)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024